cell therapi a-team aim outdo initi
immedi aftermath kite pharma sale gilead kite core
leadership reassembl take fundament limit today car-
therapi rather rest laurel recent success allogen
aim make product includ yescarta kymriah obsolet
name compani develop allogen donor-deriv product could
ts includ manufactur bandwidth cost consist allogen combin
industry-lead experi car-t clinic trial manufactur logist
could collect translat rapid develop timelin wherewith
make off-the-shelf car-t commerci realiti multipl de-risk data readout
expect next month initi outperform pt
antigen receptor t-cell therapi transform
certain leukemia lymphoma offer lifelin heavili pretreat patient
howev person natur autolog car-t product limit
scalabl believ allogen car-t technolog repres
evolutionari leap forward requir extend car-t patient
conduct survey heme/onc specialist take puls current
car-t landscap gaug enthusiasm concern allogen car-
product product consist rapid time-to-avail rank highli
physician car-t wish list note major physician would accept
margin lower safeti efficaci exchang immedi product avail
allogen car-t manufactur larg batch healthi donor t-
cell rigor character qualiti cryogen bank need
lead program focu well-valid target includ
bmca base address market non-
hodgkin lymphoma multipl myeloma see
compani primari valu driver
competit heat off-the-shelf car-t believ allogen prior
experi attent manufactur give distinct advantag
field fulli expect slate enter clinic outpac
develop linger phase hand servier
allogen pipelin seed base gene edit technolog
cellecti view pipelin partial de-risk prior
phase data acut lymphoblast leukemia notabl
retain larg stake allogen
year price histori allogen
focus
therapi treatment solid
tumor hematolog malign
analyst certif import disclosur see disclosur
approv r/r pediatr adult
peak sale
approv r/r dlbcl label expans
dlbcl respect total peak
sale
approv r/r fl peak sale
approv r/r multipl myeloma
peak sale
earlier-than-anticip regulatori approv model
potenti approv model program earlier line
therapi fl and/or mm
success develop non-model program includ
rcc nhl sclc aml
outperform rate pt reflect convict
allogen car-t therapi becom signific class
car-t therapi allogen success develop
lead product hematolog malign valuat
includ contribut nhl
mm
potenti initi phase alpha trial nhl
potenti initi phase clinic trial r/
potenti initi pivot trial r/r
potenti report initi result alpha trial
clinical/regulatori failur delay
program
termin collabor agreement servier
higher expect competit allogen
outperform rate pt base probability-weight sum-of-the-part npv methodolog model includ
contribut three differ program r/r estim po regulatori approv
treatment r/r dlbcl r/r fl po regulatori approv r/r multipl myeloma
po regulatori approv yield npv pediatr adult yield
npv dlbcl fl mm add
downsid risk invest thesi includ unexpect delay clinic develop registr file clinic
perform meet expect higher expect competit lead reduc price power
base south san francisco ca allogen biotechnolog compani
focus develop donor-deriv car-t therapi treatment
cancer unlik current approv car-t product manufactur
individu basi patient allogen allocar manufactur
healthi donor t-cell cryogen bank infus patient
demand compani pipelin seed transfer right
early-stag car-t portfolio april asset contribut
agreement exchang receiv stake compani
elig futur mileston royalti payment success develop
product cover agreement allogen clinical-stag pipelin
includ current develop partner servier
treatment pediatr adult second car-t
treatment dlbcl non-hodgkin lymphoma nhl
slate enter clinic phase trial multipl myeloma mm
evalu bcma-target slate initi
variou antigen express solid liquid tumor includ
complement cell therapi pipelin allogen also develop
proprietari antibodi may improv safeti
efficaci condit regimen patient receiv prior car-t infus
allogen recent leas facil newark ca manufactur
allocar allogen found helm experienc
manag team respons yescarta develop
initi coverag allogen outperform rate month
price target base convict scalabl avail
product consist offer allogen car-t drive adopt
domin class car-t therapi futur addit recogn
allogen leadership except qualifi success develop
commerci cell therapi pipelin
class believ car-t potenti revolution treatment
multipl hematolog malign howev recogn today
autolog car-t impart signific burden patient provid payer
alik manufactur patient-sourc t-cell inher ineffici
like contribut high price addit
day averag vein-to-vein manufactur time long patient
particularli aggress acut diseas dlbcl
underli heterogen drug product contribut heterogen
safeti efficaci profil short believ -the-shelf solut
batch-bas manufactur product character perform
up-front repres natur evolut car-t solut like would
welcom regul payer prescrib view support
survey data high-volum hematology/oncolog specialist
thu far success develop allogen car-t product
elus goal sever develop includ cellecti servier
product includ encount develop
speedbump believ technolog behind product
fundament sound believ allogen bring consider manufactur
clinic trial-design experi tabl could lead rapid
develop timelin especi
allogen focus initi effort target well valid
autolog car-t includ bcma current enrol
pediatr adult acut lymphoblast leukemia patient dual phase
trial develop spearhead servier
essenti ident develop non-hodgkin
lymphoma nhl manufactur clinic trial run allogen
expect enter clinic potenti deliv earli data
bcma-target mm partial de-risk
autolog product could enter clinic bulk
valuat center given larger potenti
market opportun nhl mm rel term allogen
develop partnership servier thesi also depend allogen
abil success expand futur label beyond
relapsed/refractori r/r nhl set autolog product
yescarta current limit
methodolog summar exhibit model includ contribut
three differ program r/r probabl
success po regulatori approv treatment r/r
dlbcl r/r fl po regulatori approv
r/r multipl myeloma po regulatori approv
elect use discount rate program given inher riski
drug develop expect timelin commerci summar
exhibit
sum-of-part valuat includ cash posit per share reflect
compani recent ipo model us project
contribut respect
project valu includ assum world-wide sale add
total npv sum per share round
detail market model see exhibit
drug develop inher riski invest thesi depend
allogen abil success develop manufactur commerci
therapi downsid risk rate could aris unexpect
delay clinic develop product registr unfavor clinic
outcom safeti event add risk allogen pipelin chang
regulatori reimburs landscap make difficult
allogen market sell product addit allogen form
collabor agreement reli partner access gene edit
technolog agreement becom impair way could affect
compani abil success commerci product
recent approv car-t therapi yescarta kymriah benefit
premium price howev could chang allogen may requir
particip pay-for-perform model therapi may advers
impact revenu estim addit model label expans
uptak therapi dlbcl present allogen focus
develop effort relapsed/refractori popul
potenti servier present updat phase data
potenti servier initi phase clinic trial r/r
potenti initi phase clinic trial alpha trial r/r non-
potenti initi clinic data alpha phase trial
initi phase clinic trial r/r multipl myeloma
compani present oppenheim co estim
pipelin clinic program
scienc cart cancer cell
car-t wide regard revolutionari treatment approach born
decad research lead academ institut car-t therapi made
commerci debut fall led two autolog product novarti
kymriah pediatr kite/gilead yescarta dlbcl aggress
form nhl view car-t differenti treatment
blood cancer due proven abil elicit durabl complet respons
highli pretreat patient run option car-t
therapi genet modifi adapt immun cell t-cell
program effici kill cancer cell make autolog car-t
therapi t-cell collect patient genet program
express target system construct see exhibit
construct attract car-t cell cancer-specif antigen stimul
activ upon bind word car-t cell immun cell
engin cellular assassin train spot cell-surfac featur
uniqu cancer
exhibit construct contain extracellular antigen-target
domain scfc intracellu co-stimulatori domain
autolog car-t manufactur begin collect immun cell
individu patient standard leukapheresi procedur t-cell
convent car-t product must sourc autolog ensur
immunolog compat construct typic introduc viral
vectoreith lentiviru -retroviru contain genet instruct
make follow viral transduct cell propag cultur
character qualiti re-infus back patient exhibit
autolog car-t product person product must care
match individu patient
yescarta kymriah demonstr high object respons rate
clinic trial enrol patient cancer exampl yescarta
approv base single-arm trial adult patient r/r aggress
b-cell nhl object respons rate orr complet
respons cr car-t efficaci safeti fundament limit
uniqu target date hand target especi
bcma proven clinic viabl note rapid activ t-
cell contribut potenti life-threaten side effect call cytokin
releas syndrom observ car-t trial
cumul car-t develop across industri
treatment-rel mortal track record approxim real-world
set perform safeti car-t larg consist
perform registr trial nastoupil et al
stark realiti autolog car-t
despit abil offer lifelin mani patient need believ
current avail autolog car-t sever seriou drawback
could rectifi off-the-shelf solut chiefli manufactur
process autolog car-t time-consum variabl costli
manufactur capac current avail car-t like suffici
heavili pretreat nhl patient believ inabl effici
scale-up product limit commerci potenti car-t earlier
treatment set larger indic addit heterogen start
materi lead real differ drug product perform
materi impact safeti efficaci case inabl expand
patient t-cell minim accept car-t result manufactur
failur final person natur autolog manufactur
undoubtedli translat high cost transfer patient/pay
two current approv car-t among expens therapi ever
approv fda cost relat autolog therapi on-going
concern healthcar system howev acknowledg recent publish
health econom studi support car-t price current level clin oncol
kite pharma abl streamlin yecarta manufactur turnaround
time less three week sever rate-limit step unavoid
includ collect shipment cell site back
expans car-t cell qualiti control screen
contaminants/adventiti agent hospit central locat near
major transport hub collect shipment step reduc
day howev car-t expans qualiti control still take sever day
lag time requir manufactur process lead patient dropout due
cancer progress per yescarta packag insert approxim
enrol patient r/r larg b-cell lymphoma treat due
progress diseas advers event follow leukapheresi similarli
kymriah approxim enrol patient dlbcl receiv
therapi product failur also occur result anoth lost opportun
treat patient need registr trial yescarta kymriah
approxim enrol patient respect receiv
treatment due manufactur roadblock exhibit manufactur issu
on-going problem novarti particular carri
registr trial commerci launch
exhibit patient miss treatment registr trial
yecarta kymriah
number patient
fail
pd death ae
number patient
fail receiv
therapi due
immedi avail
contrast autolog product allogen car-t manufactur
healthi donor t-cell large-scal product run manag indic
dose allocar gener singl product run main
step involv similar manufactur autolog car-t
addit step taken ensur donor-recipi compat exhibit
specif allocar manufactur includ genet knock-out nativ t-
cell receptor tcr necessari ensur donor-host compat prevent
graft-versus-host diseas gvhd allogen car-t gene edit
addit construct promot vivo cell expans persist
modifi safeti switch activ event acut
toxic main differ two approach highlight
exhibit manufactur autolog versu allogen car-t
allocar contain sever uniqu element rel competitor
emerg allogen space util technolog licens cellecti
pioneer field earli recogn commerci potenti
allogen product allogen car-t gene edit talen enzym
cut dna defin locat similar use
talen allow allogen make select modif car-t defin
locat genom allogen use talen technolog knock
nativ tcr note delet ensur compat
give allogen uniqu angl lymphodeplet condit prior
follow car-t infus
allogen proprietari monoclon antibodi
compani plan deploy part lymphodeplet regimen
allocar recogn host system foreign elimin
deplet matur lymphocyt recipi bodi like essenti
efficaci concurr administr antibodi allocar
may help keep endogen lymphocyt bay protect cell
destruct cancer sep addit
allogen car-t modifi express polypeptid bind
rituximab util safeti switch rapidli remov allocar
circul exhibit summar modif current includ
allogen lead product second-gener version lack
rituximab recognit domain like util futur trial
take puls physician satisfact autolog car-t gaug
comfort allogen product conduct survey high-volum
heme/onc physician routin prescrib refer patient car-t therapi
rank concern exist autolog car-t respond
note safeti profil pricing/reimburs product inconsist
top three concern exhibit note kymriah price per
patient yescarta cost usd per patient cost
inclus leukapheresi lymphodeplet manag advers event
hospital-rel cost significantli add overal cost
insuffici data say whether allocar could offer
safeti benefit exist product believ could potenti deliv
benefit concern area rank respond includ cost
exhibit survey respond main concern associ autolog car-t
similarli poll physician opinion import benefit
allogen car-t could offer nearli half respond believ
allogen car-t therapi could offer improv speed treatment well
superior manufactur bandwidth exhibit sinc allogen car-t cell
deriv healthi donor immun system impair
multipl round chemotherapi would expect cell demonstr
uniform expans profil manufactur lead uniform
predict end product
believ donor-deriv car-t could offer consist product
predict safety/efficaci profil survey respond agre
believ allogen therapi could offer consist
autolog product addit consist product
respond believ allogen product would acceler time treatment
believ manufactur bandwidth concern could allevi
believ scalabl afford allogen approach could reduc
product cost carri patient/pay approxim
respond car-t survey believ allogen product
offer lower price autolog therapi exhibit
exhibit respond take import benefit allogen car-t
nhl aggress malign survey suggest physician
may will accept margin reduc perform safeti and/or efficaci
benefit off-the-shelf approach note
minor respond survey indic would requir
off-the-shelf product meet efficaci safeti autolog therapi
exhibit contrast larg major respond indic
would accept margin lower efficaci safeti exchang
immedi avail allogen therapi treatment r/r aggress nhl
believ may actual face lower safeti efficaci bar
clear rel yescarta product approv success commerci
similarli r/r mm respond physician survey indic
would accept margin lower efficaci profil exchang conveni
off-the-shelf car-t therapi
exhibit risk/reward exchang allogen car-t nhl
car-t fda-approv autolog car-t therapi adult patient r/r diffus larg
b-cell lymphoma follow efficacy/safeti data
use profil benchmark follow see accept risk/reward exchang
off-the-shelf immedi avail car-t vs car-t r/r dlbcl patient
provid proof-of-concept
allogen pipelin took shape pfizer asset contribut agreement
april remind previous acquir right
preclin singl clinic stage asset cellecti inherit
cellecti pre-exist partnership privat held servier
hand servier phase develop sinc june
evalu two on-going phase clinic trial
pall open-label dose-
escal studi evalu adult patient r/r wherea
 explor pediatr r/r set given smaller address
patient popul rel nhl primarili view
proof-of-concept program could de-risk also note
despit success develop kymriah pediatr develop
car-t larger adult popul checker past exampl juno
forc shelv lead candid safeti concern
acknowledg safeti concern may indic specif rather
construct specif regardless believ
gener earli evid warrant investor attent
interim result pool analysi present american societi
hematolog meet show enrol patient
achiev cr across trial octob note
patient receiv mab part lymphodeplet regimen
achiev impress cr/cri note
cell expans seen four patient receiv lymphodeplet
regimen without mab given differ allogen plan
use mab futur clinic trial
safeti perspect cytokine-releas syndrom
frequent report advers event occur enrol
patient three patient experienc grade level toxic
two treatment-rel death report studi one
context sever neutropen sepi context
develop grade neutropenia and/or thrombocytopenia eight experienc
develop plan
base result trial servier plan initi phase trial
optim dose lymphodeplet regimen either
alemtuzumab expect enrol adult patient
open-label intern single-arm clinic trial r/r trial
primari endpoint measur complet remiss rate within three month
receiv patient relaps within three-month period post-
administr elig redos
separ phase trial evalu pediatr r/r
set dose weight-bas primari endpoint molecular
respons rate within two month receiv trial enrol
patient monitor month follow therapi similar
trial redos allow servier plan submit investig
plan european medicin agenc ema
assess competit landscap r/r
multipl therapi develop recent approv
antibodi antibodi drug conjug adc highlight
promis therapi exhibit given competit believ car-t
autolog allogen alik primarili reserv heavili pretreat
patient unless side effect profil significantli improv
term compet cell therapi autolu autolog car-t
modifi construct design reduc seriou side effect
includ neurotox phase trial demonstr
anti-leukemia activ absenc sever pediatr crispr
therapeut develop allogen car-t cell therapi
malign similar primari goal creat
scalabl off-the-shelf therapi singl batch use crispr-bas gene
edit technolog lack tcr class major
histocompat complex elimin risk gvhd
improv persist car-t cell respect preclin studi
prolong surviv mice xenograft tumor model
also note key collabor biotech compani advanc on-
demand allogen therapi exampl gilead
enter collabor agreement develop allogen car-t therapi
grant non-exclus licens novarti allogen tcr-defici car-
cell
exhibit competit landscap r/r
cr/cri
cr/crh
year age
cr/cri
cr/cri
oppenheim co research biomedtrack
market opportun
remark progress improv treatment
pediatr relaps still occur approxim patient inde
relaps remain one lead caus cancer-rel death children
leukemia american cancer societi estim
new case approxim case
pediatr pediatr patient b-cell precursor
believ approxim two-third r/r pediatr patient could elig
car-t therapi estim car-t elig pediatr case per year
us use treatment price per treatment substanti less
current price kymriah estim pediatr car-t market
size approxim million us
similarli adult r/r estim annual case
us estim includ patient qualifi allo-hsct
due inabl achiev complet respons induct chemotherapi
relaps follow allo-hsct receiv allo-
hsct due lack donor curr opin oncol
use treatment price per treatment estim adult
market size million us
anticip success result registr
trial could support regulatori submiss us eu project
commerci launch given proven efficaci car-t
therapi assum po pediatr adult r/r b-cell
servier collabor allogen respons total
develop cost addit allogen us commerci right servier
market eu although forese competit car-t landscap
believ allogen therapi becom domin car-t player project
captur market share estim peak us sale
pediatr adult set respect also assign lower
net price compar current market price
yescarta kymriah respect market
model pediatr b-cell r/r adult b-cell r/r
shown exhibit respect
exhibit market model pediatr
newli diagnos pediatr newli diagnos b-cell pediatr car-t elig pediatr cost market size sale penetr treat revenu profit oper expens exclud royalti royalti mileston payment mileston payment servierebt tax probabl success discount rate valu npv assum pediatr us allogen
exhibit market model adult
newli diagnos adult newli diagnos b-cell adult r/r car-t elig cost market size sale penetr treat revenu profit oper expens exclud royalti royalti mileston payment mileston payment servierebt tax probabl success discount rate valu npv assum adult us outperform
take aim yescarta
allogen develop allogen car-t candid
ident design produc use modifi manufactur
process compani plan evalu phase clinic trial
alpha treatment r/r nhl initi success
develop would like compet directli yescarta
kymriah manufactur modif made help facilit scalabl
product meet demand rel larger nhl popul similar
joint develop program servier allogen
us commerci right
phase studi design detail
allogen plan evalu single-arm phase trial alpha
patient r/r larg b-cell lymphoma includ dlbcl follicular lymphoma
fl see exhibit safeti efficaci pharmacokinet pharmacodynam
measur approxim patient expect
enrol phase trial anoth phase trial three cohort
rang total cell test phase dose
escal portion studi triple-ag lymphodeplet therapi
fludarabin cyclophosphamid administ enrol
exhibit clinic
conting success phase result allogen plan introduc second-
gener phase portion trial unlik first
gener updat version express
polypeptid recogn rituximab prior exposur rituximab may interact
rituximab bind domain manag hypothes remov
domain could prevent potenti interfer vitro
studi shown version similar characterist
competit landscap r/r nhl
similar r/r variou option avail late-stag clinic
develop r/r nhl includ autolog car-t bispecif antibodi
adc yescarta kymriah approv r/r aggress nhl
therapi demonstr long-term durabl clinic remiss
difficult-to-treat patient popul third player car-t space juno
therapeut unit celgen test phase
transcend trial relev competitor summar
cr combo
br
higher rate
market opportun
per seer statist approxim individu newli diagnos
nhl us among subtyp non-hodgkin
lymphoma diffus larg b-cell lymphoma dlbcl largest compris
nhl case per year blood jan dlbcl
curabl front line chemotherapi regimen typic r-chop major
patient howev relaps chemo refractori
hsct use lymphodeplet dose chemotherapi standard
care second-lin treatment option patient relaps follow induct
chemotherapi howev order qualifi patient must chemosensit
diseas given proven deep durabl respons current approv
autolog car-t therapi believ car-t class play signific
role earlier line therapi support hypothesi result car-t
survey show approxim respond believ car-t
therapi either moder use case wide use
case furthermor random trial gilead phase trial
current evalu car-t therapi second-lin stand care r/r
dlbcl result believ could serv patient
refractori and/or relaps line therapi
summar exhibit estim approxim
second-lin address dlbcl patient anoth patient
relaps follow second line later therapi assum rel discount
treatment price estim peak market opportun allo-
dlbcl us assum peak penetr per
market opportun fl
estim market opportun fl use number
allogen stem cell transplant perform per year benchmark us
approxim allo-hsct perform year per cibmtr statist
use treatment price estim us car-t market size
r/r follicular lymphoma believ could approv
indic estim peak sale exhibit
exhibit market model dlbcl
newli diagnos dlbcl patient refractori patient relaps address dlbcl patient r/r car-t elig dlbcl patient cost r/r market size r/r sale r/r market r/r patient market size sale market patient revenu profit oper expens exclud royalti royalti mileston payment mileston payment servierebt tax probabl success discount rate valu npv assum dlbcl us
exhibit market model fl
newli diagnos adult fl r/r car-t elig cost market size sale penetr treat revenu profit oper expens exclud royalti royalti mileston payment mileston payment servierebt tax probabl success discount rate valu npv assum fl us allogen
area car-t
multipl myeloma cancer plasma cell lineag origin bone
marrow diseas character abnorm growth plasma cell
increas cell domin cell type bone marrow
result excess abnorm immunoglobulin crowd plasma cell
also interfer hematopoiesi lead cytopenia caus fatigu
weak pallor patient although new therapi avail
treatment mm relaps rate high cure diseas
keep relapsed/refractori patient aliv repres area signific
clinic trial autolog anti-bcma car-t therapi shown promis
earli result r/r mm rel standard care exampl bluebird bio
celgen present robust respons rate dose cell
asco annual meet orr cr/scr
vgpr trial median month median
dor month data among infus patient includ low incid
grade grade neurotox
separ legend biotech subsidiari genscript develop lcar-
car-t cell therapi exhibit two bcma target domain
goal demonstr cell activ tumor
demonstr orr cr vgpr mpf
patient month mpf achiev mrd-
neg cr month note mo reach patient
treat patient aliv month safeti although
occur patient grade case high-grad
neurotox report journal hematolog oncolog
left bcma car-t race novarti recent announc
partnership newcom poseida invest seri
fund round eye poseida lead product bcma-target car-t
product slate enter phase year
develop plan timelin
allogen develop allocar mm
genet edit elimin express tcr
help reduc risk gvhd potenti extend vivo
persist construct also includ rituximab recognit domain
scfv linker domain serv on-off switch follow
allogen plan submit investig new drug applic initi
phase clinic trial target bcma treatment
patient r/r diseas sever clinic studi autolog car-t cell
therapi target bcma produc promis result indic
see bcma highli de-risk target preclin studi
establish efficaci xenograft model exhibit caveat
come preclin asset believ could play import
role r/r mm especi manufactur greater consist
reduc cost rel autolog product allogen plan phase
clinic trial evalu pharmacokinet pharmacodynam
paramet patient r/r mm help guid recommend phase
dose allogen plan enrol patient progress least three
line prior therapi alpha trial expect patient receiv
lymphodeplet therapi fludarabin cyclophosphamid
exhibit show anti-tumor activ preclin model
allogen myeloma cell line inject immuno-defici mice
competit landscap r/r mm
bcma attract target evalu sever develop
variou clinic stage fda approv anti-bcma car-t therapi
yet see bluebird/celgen leader space base
promis phase data expect see pivot data celgen
karmma trial year-end legend biotech also shown strong
phase result addit sever promis candid target bcma
highlight oral abstract session meet includ
see
bispecif yet match activ
car-t anti-bcma bispecif gener earli efficaci
safeti data could repres real threat car-t profil hold
larger trial report meet patient treat
includ stringent mrd neg one dose-limit
toxic dlt data clearli encourag note
portabl pump
exhibit competit landscap mm
compani report oppenheim co research
orr
market opportun
per seer surveil epidemiolog end result statist
approxim new case multipl myeloma diseas
respons death us primarili affect elderli patient
significantli patient diagnos age
diagnos age
despit well-establish efficaci autolog car-t therapi
respond physician survey indic would accept margin
lower efficaci profil exchang use off-the-shelf product believ
off-the-shelf avail could repres key advantag
increasingli crowd competit landscap base manag track
record rapidli advanc clinic candid believ allogen could
success commerci r/r mm potenti commerci
launch estim market size patient per year us
patient per year eu base estim number
multipl myeloma patient death per year model price
us eu allogen world-wide commerci
right model peak pale us
eu assign po rate discount rate
arriv npv per share market model r/r mm
shown exhibit
exhibit market model multipl myeloma
newli diagnos mm mm cost market size sale penetr treat newli diagnos mm mm cost market size sale penetr treat sale profit oper expens exclud royalti royalti mileston payment tax probabl success discount rate valu npv assum mm us eu outperform
allogen declar sever addit preclin program includ
allocar acut myeloid leukemia allocar
nhl allocar renal cell carcinoma
target allocar small cell lung cancer due earli stage lack
clariti development timelin asset exclud
valuat time
follow execut pfizer agreement allogen patent portfolio
includ intellectu properti cover lead program well research-
stage candid compani ip portfolio includ right cellecti talen
gene-edit technolog compos patent pend patent
applic sole own allogen co-own servier co-own
cellecti exclus licens exclus licens servier
exclus licens cellecti
highlight exhibit allogen maintain us commerci right lead
product candid includ
compani also maintain world-wide right
program allogen exclus licens
servier commerci develop us bcma program
allogen hold exclus world-wide right
allogen complet ipo octob rais gross proce
includ compani cash cash equival posit
report estim pro forma cash posit could sustain
oper ad dilut rais model could
sustain compani profit growth estim
project net loss
per share respect expect see increas cash burn
associ increas sg reflect compani clinic
expens program hematolog malign solid tumor
allogen clinic pipelin consist earli stage candid
project revenu model project revenu
us peak sale non-risk adjust
nhl respect expect candid approv
contribut first-year revenu similarli model
approv r/r mm product could gener total peak non-risk adjust
sale us eu
estim expens sg expens
expect total oper expens per year
assum cog allogen allogen car-t therapi lower
estim cost autolog cell therapi gilead yescarta
also incorpor single-digit royalti mileston payment
allogen partner market model
presid chief execut offic
dr belldegrun leader develop novel cancer treatment
close involv found advanc sever success privat
public biopharmaceut compani prior allogen dr belldegrun
serv chairman presid chief execut offic kite pharma
acquisit found agensi inc
biotechnolog compani serv found chairman board
member acquir astella pharma
found vice-chairman board director chairman
scientif advisori board cougar biotechnolog acquir
johnson johnson dr belldegrun chairman arno therapeut
river group formerli theracoat current serv
board member teva pharmaceut cell design lab
also member parker institut cancer immunotherapi strateg
advisori group addit univers california lo angel ucla
dr belldegrun professor urolog hold roy carol doumani chair
urolog oncolog director ucla institut urolog oncolog
david geffen school medicin prior join ucla research
fellow surgic oncolog immunotherapi nation cancer
institute/nih work dr steven rosenberg dr belldegrun earn
hebrew univers hadassah medic school jerusalem
undertook postgradu studi immunolog weizmann institut
scienc resid urolog surgeri brigham women
hospit harvard medic school boston author sever
book oncolog scientif medic paper relat
urolog cancer immunotherapi gene therapi cancer vaccin
certifi american board urolog fellow american
colleg surgeon american associ genitourinari surgeon
dr chang industry-lead track record innov field
oncolog drug develop recent dr chang serv execut vice
presid chief medic offic kite pharma gilead
compani led develop yescarta axicabtagen ciloleucel
previous held senior leadership role
includ vice presid global develop head hematology-
oncolog time spearhead person therapi strategi
underlay success vectibix panitumumab also provid therapeut
area leadership pivot program blincyto blinatumomab bispecif t-
cell engag antibodi acut lymphocyt leukemia imlyg talimogen
laherparepvec first-of-its-kind oncolyt immunotherapi melanoma prior
join dr chang held dual appoint associ professor
medicin microbiolog immunolog molecular genet david
geffen school medicin univers california lo angel
obtain degre biolog massachusett institut technolog
ph degre stanford univers dr chang complet
internship resid intern medicin brigham women hospit
fellowship medic oncolog dana-farb cancer institut harvard
medic school howard hugh medic institut postdoctor
barbra sasu chief scientif offic allogen dr sasu join allogen
cso april barbra receiv ph paterson institut
cancer research manchest uk laboratori michael dexter
fr conduct postdoctor research harvard medic school
laboratori keith blackwel ph barbra join
work normal malign hematolog initi later expand focu
includ immune-oncolog emphasi t-cell redirect therapi
specif bite molecul join becom involv
larg molecul immuno-oncolog includ t-cell redirect program
eric schmidt ph chief financi offic allogen eric previous
manag director senior biotechnolog analyst cowen
compani prior join cowen eric vice presid research
analyst cover biotechnolog sector ub secur join
research firm hold chemistri univers
pennsylvania ph biochemistri massachusett institut
technolog serv visit committe depart
figur thousand except per share revenu revenuetot revenu expens good sold research develop sell gener administr oper loss fair valu convert note interest interest loss incom tax benefit incom loss comprehens net comprehens per share share outstand co mark breidenbach allogen
figur thousand except per share cash expens current total current leas right-of-us equiment asset long-term current liabil account accru current converitbl note total current liabil long-term commit conting convert prefer subcript receiv prefer stockhold equiti common paid-in comprehens incom stockhold equiti liabil stockhold co mark breidenbach outperform
stock price compani mention report may
genscript biotech parent compani legend biotech otcmkts-gnnsf cover
